Name: | lumiracoxib |
---|---|
PubChem Compound ID: | 151166 |
Molecular formula: | C15H13ClFNO2 |
Molecular weight: | 293.72 g/mol |
Synonyms: |
Prexige; COX189; 2-((2-Chloro-6-fluorophenyl)amino)-5-methylbenzeneacetic acid; Benzeneacetic acid, 2-((2-chloro-6-fluorophenyl)amino)-5-methyl-; Lumiracoxib (USAN); D03714; 220991-20-8; Lumiracoxib; COX 189; COX-189.
show more » |
Name: | lumiracoxib |
---|---|
Name (isomeric): | DB01283 |
Drug Type: | small molecule |
Synonyms: |
COX 189
|
Brand: | Prexige, Prexige (Novartis) |
Category: | Cyclooxygenase Inhibitors, Cyclooxygenase 2 Inhibitors |
CAS number: | 220991-20-8 |
Indication: | For the acute and chronic treatment of the signs and symptoms of osteoarthritis of the knee in adults. |
---|---|
Pharmacology: |
Lumiracoxib has a different structure from the standard COX-2 inhibitors (e.g. celecoxib). It more closely resembles the structure of diclofenac (one chlorine substituted by fluorine, the phenylacetic acid has another methyl group in meta position), making it a member of the arylalkanoic acid family of NSAIDs. It binds to a different site on the CO...
show more » |
Mechanism of Action: | The mechanism of action of lumiracoxib is due to inhibition of prostaglandin synthesis via inhibition of cyclooygenase-2 (COX-2). Lumiracoxib does not inhibit COX-1 at therapeutic concentrations. |
Absorption: | Rapidly absorbed following oral administration, with an absolute oral bioavailablity of 74%. |
Protein binding: | Highly bound to plasma proteins (>= 98%). |
Biotransformation: | Hepatic oxidation and hydroxylation via CYP2C9. Three major metabolites have been identified in plasma: 4'-hydroxy-lumiracoxib, 5-carboxy-lumiracoxib, and 4'-hydroxy-5-carboxy-lumiracoxib. |
Half Life: | Terminal half-life is approximately 4 hours. |
Toxicity: | Single oral doses in mice and rats resulted in mortality and/or moribundity at doses of 600 mg/kg and 500 mg/kg, respectively. Single intraperitoneal doses in mice and rats results in mortality/moribundity at 750 mg/kg and 1000 mg/kg, respectively. The maximum non-lethal single oral and intraperitoneal dose in mouse was 300 mg/kg and 250 mg/kg, respectively. In the rat it was 150 mg/kg and 250 mg/kg, respectively. |
Affected organisms: | Humans and other mammals |
Food interaction: |
| ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Drug interaction: |
|